GlassScriptPhysician profile
Victor H Cantero
NPI 1972772994
$2,011.00
in general payments reported to CMS, 2019-2025
26 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $140 · 2021: $596 · 2022: $572 · 2023: $192 · 2024: $181 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $711.15 | 2019-2024 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $206.41 | 2022-2024 | |
| Coopersurgical, INC. | $113.14 | 2021-2025 | Paragard T 380a, Summit Doppler |
| Intuitive Surgical, INC. | $111.77 | 2019-2021 | |
| Lupin INC. | $85.56 | 2019-2021 | |
| Avion Pharmaceuticals | $77.89 | 2021-2022 | |
| Myovant Sciences INC. | $76.60 | 2021-2022 | |
| Hologic Sales and Service, LLC | $67.14 | 2019-2025 | Aptima |
| Shield Therapeutics INC | $57.70 | 2022-2023 | Accrufer |
| Daiichi Sankyo INC. | $47.49 | 2022 | |
| Duchesnay USA Incorporated | $46.26 | 2019 | |
| Allergan, INC. | $45.29 | 2019 | |
| Ge Healthcare | $44.68 | 2020-2024 | |
| Pfizer INC. | $40.05 | 2019-2022 | |
| Exeltis, USA INC. | $34.70 | 2025 | Slynd |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $31.89 | 2025 | Veozah |
| Therapeuticsmd, INC. | $31.34 | 2021 | |
| Mylan Pharmaceuticals INC. | $31.29 | 2022 | |
| Baxter Healthcare | $24.59 | 2021 | |
| Dilon Technologies, INC. | $23.41 | 2024 | Hemoblast Bellows |
| Sumitomo Pharma America, INC. | $22.02 | 2023 | Myfembree |
| Millicent US INC | $18.91 | 2024 | Intrarosa, Femring |
| Scynexis, INC. | $18.00 | 2022 | |
| Becton, Dickinson and Company | $16.47 | 2022 | |
| Biogen, INC. | $13.88 | 2025 | Zurzuvae |
| Mission Pharmacal Company | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Cantero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.